Janssen is working alongside Arrowhead Pharmaceuticals to develop and commercialise ARO-HBV – a Phase 1/2 subcutaneous, ribonucleic acid interference (RNAi) therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.
Arrowhead will complete the ongoing Phase 1/2 clinical trial for ARO-HBV, a next-generation RNAi therapy candidate which is designed to silence HBV gene products by specifically targeting two regions of the HBV genome.
Janssen will lead the clinical development from Phase 2b onwards. Arrowhead will receive an initial upfront payment, potential development and commercial milestone payments and potential future royalties.
Separately, Johnson & Johnson Innovation – JJDC, Inc. – will make an equity investment in Arrowhead.
Janssen and Arrowhead also agreed to a research collaboration to develop RNAi therapeutics directed against additional targets using Arrowhead’s proprietary Targeted RNAi Molecule (TRiM) platform.
If Janssen exercises its option for such RNAi therapeutics, Arrowhead will be eligible to receive additional payments.